S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
FRA:FRE

Fresenius SE & Co. KGaA Stock Forecast, Price & News

€41.12
-0.20 (-0.48 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
€40.98
€41.40
50-Day Range
€40.50
€47.44
52-Week Range
€60.16
€80.00
Volume846,868 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FRE News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.


Fresenius SE & Co. KGaA logo

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.47 out of 5 stars

Analyst Opinion: 2.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Fresenius SE & Co. KGaA (FRA:FRE) Frequently Asked Questions

Is Fresenius SE & Co. KGaA a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co. KGaA in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fresenius SE & Co. KGaA stock.
View analyst ratings for Fresenius SE & Co. KGaA
or view top-rated stocks.

What stocks does MarketBeat like better than Fresenius SE & Co. KGaA?

Wall Street analysts have given Fresenius SE & Co. KGaA a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fresenius SE & Co. KGaA wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Fresenius SE & Co. KGaA's stock been impacted by Coronavirus (COVID-19)?

Fresenius SE & Co. KGaA's stock was trading at €36.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FRE stock has increased by 14.2% and is now trading at €41.12.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for FRE?

15 Wall Street analysts have issued twelve-month price objectives for Fresenius SE & Co. KGaA's shares. Their forecasts range from €39.00 to €65.00. On average, they expect Fresenius SE & Co. KGaA's share price to reach €48.38 in the next year. This suggests a possible upside of 17.7% from the stock's current price.
View analysts' price targets for Fresenius SE & Co. KGaA
or view top-rated stocks among Wall Street analysts.

Who are Fresenius SE & Co. KGaA's key executives?

Fresenius SE & Co. KGaA's management team includes the following people:
  • Mr. Stephan Sturm, CEO, Pres & Chairman of Management Board - Fresenius Management SE (Age 58, Pay $3.56M)
  • Ms. Rachel Clare Empey, CFO & Member of Management Board - Fresenius Management SE (Age 45, Pay $2.85M)
  • Dr. Francesco De Meo, Member of Management Board - Fresenius Management SE (Age 58, Pay $2.45M)
  • Dr. Ernst Wastler, Member of Management Board - Fresenius Management SE (Age 63, Pay $1.58M)
  • Mr. Rice Powell, Member of Management Board - Fresenius Management SE (Age 66, Pay $4.05M)
  • Dr. Sebastian Biedenkopf, Chief Legal & Compliance Officer, Insurance, HR, Labor Relations Director and Member of Mgmt. Board (Age 56, Pay $604k)
  • Mr. Michael Sen, Member of Management Board (Age 53)
  • Mr. Markus Georgi, Sr. VP of Investor Relations

What other stocks do shareholders of Fresenius SE & Co. KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius SE & Co. KGaA investors own include Illumina (ILMN), Daimler (DAI), Endologix (ELGX), Allianz (ALV), (APA), Cambrex (CBM), Linde (LIN), Alibaba Group (BABA), General Electric (GE) and HeidelbergCement (HEI).

What is Fresenius SE & Co. KGaA's stock symbol?

Fresenius SE & Co. KGaA trades on the FRA under the ticker symbol "FRE."

What is Fresenius SE & Co. KGaA's stock price today?

One share of FRE stock can currently be purchased for approximately €41.12.

How many employees does Fresenius SE & Co. KGaA have?

Fresenius SE & Co. KGaA employs 310,842 workers across the globe.

What is Fresenius SE & Co. KGaA's official website?

The official website for Fresenius SE & Co. KGaA is www.fresenius.de.

Where are Fresenius SE & Co. KGaA's headquarters?

Fresenius SE & Co. KGaA is headquartered at Else-Kroener-Str. 1, BAD HOMBURG VOR DER HOEHE, 61352, Germany.

How can I contact Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA's mailing address is Else-Kroener-Str. 1, BAD HOMBURG VOR DER HOEHE, 61352, Germany. The company can be reached via phone at +49-6172-6080.


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.